AbbVie reported Q3 2024 global net revenues of $14.5 billion, up 3.8% year-over-year, with operating earnings of $3.8 billion and diluted EPS of $0.88. Skyrizi revenues surged 50.8% to $3.2 billion and Rinvoq grew 45.3% to $1.6 billion, while Humira sales declined 37.2% to $2.2 billion due to biosimilar competition. The company completed strategic acquisitions of ImmunoGen and Cerevel Therapeutics during the quarter.The company's immunology portfolio showed strong momentum, with Skyrizi and Rinvoq demonstrating robust market share gains across all indications. Aesthetics revenue remained resilient with Botox Cosmetic growing 8.2% to $671 million, while neuroscience products like Vraylar and Botox Therapeutic delivered solid growth of 16.6% and 13.4% respectively. Operating margin improved significantly to 71% from 53% in the prior year.Looking ahead, AbbVie raised its quarterly dividend by 5.8% to $1.64 per share and maintained strong R&D investments across its pipeline. The company's cash flow from operations was $11.8 billion for the first nine months, while completing strategic acquisitions to strengthen its neuroscience and oncology portfolios. Management expects continued growth momentum from new products to offset Humira erosion.

AbbVie reported Q3 2024 global net revenues of $14.5 billion, up 3.8% year-over-year, with operating earnings of $3.8 billion and diluted EPS of $0.88. Skyrizi revenues surged 50.8% to $3.2 billion and Rinvoq grew 45.3% to $1.6 billion, while Humira sales declined 37.2% to $2.2 billion due to biosimilar competition. The company completed strategic acquisitions of ImmunoGen and Cerevel Therapeutics during the quarter.The company's immunology portfolio showed strong momentum, with Skyrizi and Rinvoq demonstrating robust market share gains across all indications. Aesthetics revenue remained resilient with Botox Cosmetic growing 8.2% to $671 million, while neuroscience products like Vraylar and Botox Therapeutic delivered solid growth of 16.6% and 13.4% respectively. Operating margin improved significantly to 71% from 53% in the prior year.Looking ahead, AbbVie raised its quarterly dividend by 5.8% to $1.64 per share and maintained strong R&D investments across its pipeline. The company's cash flow from operations was $11.8 billion for the first nine months, while completing strategic acquisitions to strengthen its neuroscience and oncology portfolios. Management expects continued growth momentum from new products to offset Humira erosion.